We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Much to Metabolize: The 21st Century Cures Act Introduces Numerous Changes to FDA’s Drug Regulatory Framework to Spur Development of New Treatments

14 December 2016

Pharmaceutical and Biotechnology Alert

The 21st Century Cures Act (Cures Act) has become law with measures designed to deliver new cures and treatments to patients.  Among these measures are a broad range of changes to the U.S. Food and Drug Administration’s regulation of drugs and biologics. This alert highlights key areas of the Cures Act that will affect pharmaceutical and biotechnology companies, including provisions related to clinical trials, use of real world evidence, patient-focused drug development, health care economic information, summary level review, combination products, expanded access, drugs for rare diseases, and regenerative therapies.

Read more.


Loading data